0.861
Clearside Biomedical Inc stock is traded at $0.861, with a volume of 96,760.
It is down -1.05% in the last 24 hours and down -14.75% over the past month.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
See More
Previous Close:
$0.8701
Open:
$0.88
24h Volume:
96,760
Relative Volume:
0.39
Market Cap:
$65.30M
Revenue:
$8.23M
Net Income/Loss:
$-32.49M
P/E Ratio:
-1.6245
EPS:
-0.53
Net Cash Flow:
$-19.91M
1W Performance:
-11.79%
1M Performance:
-14.75%
6M Performance:
-30.00%
1Y Performance:
-47.18%
Clearside Biomedical Inc Stock (CLSD) Company Profile
Name
Clearside Biomedical Inc
Sector
Industry
Phone
678-270-3631
Address
900 NORTH POINT PARKWAY, ALPHARETTA, GA
Compare CLSD with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CLSD
Clearside Biomedical Inc
|
0.861 | 65.30M | 8.23M | -32.49M | -19.91M | -0.53 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-21-24 | Initiated | Chardan Capital Markets | Buy |
Jun-25-24 | Initiated | Oppenheimer | Outperform |
Dec-15-21 | Resumed | Wedbush | Outperform |
Jul-29-21 | Initiated | H.C. Wainwright | Buy |
May-13-20 | Initiated | ROTH Capital | Buy |
Aug-09-19 | Downgrade | Needham | Buy → Hold |
Nov-05-18 | Downgrade | Cowen | Outperform → Market Perform |
Nov-05-18 | Downgrade | JP Morgan | Overweight → Underweight |
Nov-05-18 | Downgrade | Stifel | Buy → Hold |
Mar-06-18 | Reiterated | Needham | Buy |
May-25-17 | Initiated | JMP Securities | Mkt Outperform |
Feb-24-17 | Initiated | JP Morgan | Overweight |
Nov-10-16 | Reiterated | Needham | Buy |
Oct-24-16 | Reiterated | Stifel | Buy |
View All
Clearside Biomedical Inc Stock (CLSD) Latest News
Clearside Biomedical to Report Fourth Quarter and Full Year - GlobeNewswire
Clearside Biomedical, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025 - Nasdaq
Clearside Biomedical Q4 Earnings: Key Date Announced for Critical Year-End Financial Results - StockTitan
Clearside Biomedical (CLSD) Projected to Post Earnings on Tuesday - Defense World
HC Wainwright Reiterates “Buy” Rating for Clearside Biomedical (NASDAQ:CLSD) - Defense World
Clearside Biomedical, Inc. to Host Earnings Call - ACCESS Newswire
Clearside Biomedical Announces Successful End-of-Phase 2 - GlobeNewswire
Buy Rating on Clearside Biomedical: Strategic Advancements in CLS-AX Program for wAMD - TipRanks
Promising Potential of Clearside Biomedical’s CLS-AX Treatment Justifies Buy Rating - TipRanks
Clearside Biomedical (CLSD) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Clearside Biomedical announces successful End-of-Phase 2 meeting for CLS-AX - TipRanks
Can This New Wet AMD Treatment Challenge the $12B Market? FDA Says Yes to Phase 3 - StockTitan
Clearside Biomedical stock hits 52-week low at $0.79 - Investing.com
Clearside Biomedical Inc. Revolutionizes Panuveitis Treatment With Innovative Xipere Product: Key Trend in ... - WhaTech
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of “Buy” by Brokerages - Defense World
Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Buys $13,800.00 in Stock - MarketBeat
Clearside Biomedical director Thorp Clay buys $13,800 in stock By Investing.com - Investing.com South Africa
Director Makes Bold Move with New Stock Purchase in Clearside Biomedical - TipRanks
Clearside Biomedical director Thorp Clay buys $13,800 in stock - Investing.com India
Clearside Biomedical's SWOT analysis: innovative eye treatment stock faces pivotal trial - MSN
Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, - GlobeNewswire
China accepts Arctic Vision's drug application for eye treatment By Investing.com - Investing.com South Africa
Clearside Biomedical’s partner in China granted acceptance of arcatus NDA - TipRanks
Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema - GlobeNewswire
China Opens Door to Revolutionary Eye Treatment: What Makes ARCATUS a Game-Changer in $1B+ Market? - StockTitan
Clearside Biomedical (NASDAQ:CLSD) Stock Price Crosses Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Clearside reports progress in wet AMD treatment trials - MSN
Clearside Biomedical Announces Additional Data from the - GlobeNewswire
Clearside reports progress in wet AMD treatment trials By Investing.com - Investing.com Nigeria
Clearside's Eye Treatment Breakthrough: 6-Month Freedom from Injections for Majority of AMD Patients - StockTitan
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives $5.33 Average Price Target from Analysts - MarketBeat
Selling Your Clearside Biomedical Inc (CLSD) Stock? Here’s What You Need To Know - Stocks Register
Clearside Biomedical (NASDAQ:CLSD) Share Price Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference - The Manila Times
Clearside Biomedical to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference - Nasdaq
Clearside Biomedical to Participate in Fireside Chat at the - GlobeNewswire
Inside Clearside Biomedical's Strategic Vision: CEO Fireside Chat at Major Healthcare Conference - StockTitan
Clearside Biomedical Highlights CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial at Upcoming Conferences - Nasdaq
Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program - GlobeNewswire
Clearside Biomedical Announces Multiple Medical Meeting - GlobeNewswire
Assenagon Asset Management S.A. Sells 125,190 Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) - Defense World
Clearside Biomedical (NASDAQ:CLSD) Stock Price Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
Clearside Biomedical (CLSD) Stock Price, News & Analysis - MarketBeat
Clearside Biomedical Announces its Asia-Pacific Partner, - GlobeNewswire
Clearside Biomedical Inc Stock (CLSD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):